All In Biotech

Drug Trial Radar · NCT06064877

A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma

A Multicenter, Randomized, Double Blind, Placebo - Controlled, Phase 3 Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV -Negative Head and Neck Squamous Cell Carcinoma. (FIERCE-HN)

Last checked: Nov 20, 2026Latest source record: Apr 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 410 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

410

Planned (sponsor's estimate)

Start

Jan 11, 2024

Primary completion

Aug 2027

Study completion Nov 2027

Sponsor

Lead sponsor
AVEO Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Oct 3, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare the efficacy and safety of ficlatuzumab plus cetuximab compared to placebo plus cetuximab in participants with recurrent/metastatic (R/M) HPV-negative Head and Neck Cancer. The primary hypothesis is that ficlatuzumab combined with cetuximab is superior to cetuximab alone in terms of progression-free survival and/or overall survival.

Conditions

  • Metastatic Head-and-neck Squamous-cell Carcinoma
  • Recurrent Head and Neck Squamous Cell Carcinoma

Interventions

  • FiclatuzumabBiological

    Ficlatuzumab (AV-299) is a humanized hepatocyte growth factor (HGF) inhibitory immunoglobulin G1 (IgG1) monoclonal antibody (mAb).

  • CetuximabBiological

    Cetuximab is an epidermal growth factor receptor (EGFR) antagonist.

  • PlaceboOther

    Placebo for this study will be normal saline

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To compare the efficacy by overall survival of ficlatuzumab plus cetuximab vs placebo plus cetuximab in participants with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)Time frame: From Randomization until death from any cause (Approximately 44 months)

Locations

112 sites in 18 countries. Site status is shown where the registry gives one.

  • Banner MD Anderson Cancer Center

    Gilbert, Arizona · Recruiting

  • The University of Arizona Cancer Center

    Tucson, Arizona · Recruiting

  • University of California Los Angeles

    Los Angeles, California · Recruiting

  • Yale School of Medicine - Smilow Cancer Hospital

    New Haven, Connecticut · Recruiting

  • The George Washington University

    Washington D.C., District of Columbia · Recruiting

  • AdventHealth Medical Group Oncology & Hematology at Orlando

    Orlando, Florida · Recruiting

  • Moffitt Cancer Center

    Tampa, Florida · Recruiting

  • Emory University

    Atlanta, Georgia · Recruiting

  • University of Illinois Cancer Center

    Chicago, Illinois · Recruiting

  • University of Kansas Cancer Center

    Westwood, Kansas · Recruiting

  • Mary Bird Perkins Cancer Center

    Baton Rouge, Louisiana · Recruiting

  • MaineHealth Institute for Research

    South Portland, Maine · Recruiting

  • University of Maryland

    Baltimore, Maryland · Recruiting

  • Massachusetts General Hospital

    Boston, Massachusetts · Recruiting

  • Dana Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • Siteman Cancer Center - Washington University

    St Louis, Missouri · Recruiting

  • Northwell Health Cancer Institute

    Lake Success, New York · Recruiting

  • Manhattan Eye, Ear & Throat Hospital

    New York, New York · Recruiting

  • Montefiore Medical Center

    The Bronx, New York · Withdrawn

  • University of Cincinnati - UC Health Barrett Cancer Center

    Cincinnati, Ohio · Withdrawn

  • Ohio State University, James Cancer Hospital and Solove Research Institute

    Columbus, Ohio · Recruiting

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania · Recruiting

  • University of Pittsburgh Medical Center - Hillman Cancer Center

    Pittsburgh, Pennsylvania · Recruiting

  • Medical University of South Carolina (MUSC)

    Charleston, South Carolina · Recruiting

  • MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • Oncology Consultants

    Houston, Texas · Recruiting

  • VCU Massey Cancer Center

    Richmond, Virginia · Recruiting

  • Medical College of Wisconsin - Froedtert Hospital Cancer Center

    Milwaukee, Wisconsin · Terminated

  • St George Hospital

    Kogarah, New South Wales, Australia · Recruiting

  • St. Vincent's Hospital

    Sydney, New South Wales, Australia · Recruiting

  • Princess Alexandra Hospital

    Brisbane, Queensland, Australia · Recruiting

  • St. John of God Murdoch Hospital

    Murdoch, Western Australia, Australia · Recruiting

  • CHU Liège

    Liège, Belgium · Recruiting

  • CHU Universite Catholique de Louvain

    Namur, Belgium · Recruiting

  • Vitaz-Sint-Niklaas Moerland

    Sint-Niklaas, Belgium · Recruiting

  • University Hospital

    Panagyurishte, Bulgaria · Withdrawn

  • Tom Baker Cancer Centre (Alberta Health Services)

    Calgary, Alberta, Canada · Recruiting

  • Cross Cancer Institute

    Edmonton, Alberta, Canada · Recruiting

  • The Ottawa Hospital Cancer Centre

    Ottawa, Ontario, Canada · Withdrawn

  • Princess Margaret Cancer Center - University Health Network

    Toronto, Ontario, Canada · Recruiting

Showing 40 of 112 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.